AstraZeneca vs Thermo Fisher Scientific: Fair Value & Quality
Both stocks run through our valuation models. Here is how AstraZeneca (AZN) and Thermo Fisher Scientific (TMO) compare, as of Aug 16, 2026.
As of Aug 16, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: AstraZeneca trades at $156 versus a fair value of $127 (-19%), while Thermo Fisher Scientific trades at $588 versus $308 (-48%).
AstraZeneca
AZN · USD · Health Care
-19%
upside to fair value
overvalued
Price$156
Fair Value$127
Quality69/100
Thermo Fisher Scientific
TMO · USD · Health Care
-48%
upside to fair value
overvalued
Price$588
Fair Value$308
Quality63/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
AstraZenecaThermo Fisher Scientific
Valuation
23.5×P/E (TTM)29.5×
4.49×P/S (TTM)4.41×
5.58×P/B3.74×
14.5×EV/EBITDA20.0×
1.36×PEG1.74×
1.8%Dividend yield0.3%
$3.20Dividend per share$1.76
Profitability
17%Net margin15%
28%Operating margin18%
23%Return on equity14%
8%Return on assets5%
Growth
13%Revenue growth (YoY)6%
9.8%Avg. growth/yr (3Y)-0.3%
17.2%Avg. growth/yr (5Y)6.7%
Balance & size
0.51×Debt / equity0.67×
$271BMarket cap$199B
healthyGrowth qualityhealthy
AstraZeneca leads: 12 to 2 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
AstraZenecaof which business quality 65 · market factors 47Thermo Fisher Scientificof which business quality 60 · market factors 67
ProfitabilityMargins and returns on capital today
63
43
Quality GrowthAre margins and returns improving?
65
31
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
60
79
Low VolatilityCalm price path (market factor)
86
69
MomentumPrice trend over the last 3–12 months (market factor)
29
65
52W MomentumDistance to the 52-week high (market factor)
34
68
Net IssuanceBuybacks instead of dilution
82
97
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
AstraZeneca
DCF Models$116
Earnings-Based$60.23
Multiples$125
Asset-Based$21.03
Growth DCF$100
Economic Profit$75.73
Growth Earnings$129
22 of 24 models see the stock below the current price.
Thermo Fisher Scientific
DCF Models$354
Earnings-Based$203
Multiples$308
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$341
24 of 24 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
AstraZeneca
Bear $72.51Fair Value $127Bull $173
$156 = current price (white tick)
Thermo Fisher Scientific
Bear $171Fair Value $308Bull $385
$588 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
AstraZeneca · Health Care
Quality score69 · Top 25%
Fair value upside-19% · above median
Thermo Fisher Scientific · Health Care
Quality score63 · Top 25%
Fair value upside-48% · below median
Bottom line
As of Aug 16, 2026, Fair Value Calculator sees AstraZeneca as the less overvalued of the two: AstraZeneca trades at $156 versus a fair value of $127 (-19%), while Thermo Fisher Scientific trades at $588 versus $308 (-48%).
AstraZeneca has the higher quality score (69/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
